Constitutive membrane association potentiates activation of Bruton tyrosine kinase

被引:0
|
作者
Tianjian Li
David J Rawlings
Hyunsun Park
Roberta M Kato
Owen N Witte
Anne B Satterthwaite
机构
[1] Molecular Biology Institute,Department of Pediatrics, Division of Immunology/Rheumatology
[2] University of California,Department of Microbiology and Molecular Genetics
[3] School of Medicine,undefined
[4] University of California,undefined
[5] Howard Hughes Medical Institute,undefined
[6] University of California,undefined
[7] University of California,undefined
来源
Oncogene | 1997年 / 15卷
关键词
Btk; pleckstrin homology domain; membrane targeting; transformation;
D O I
暂无
中图分类号
学科分类号
摘要
Mutations in the nonreceptor tyrosine kinase Btk result in the B cell immunodeficiencies X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. Genetic and biochemical evidence implicates Btk as a key component of several B cell signaling pathways. Activation of Btk by a point mutation (E41K) within the PH domain (Btk*) results in fibroblast transformation and is correlated with increased membrane localization of Btk. When wild type Btk is activated by coexpression with Lyn, the tyrosine phosphorylated pool of Btk is highly enriched in the membrane fraction. To determine whether membrane association is sufficient to activate Btk, we targeted Btk to the plasma membrane using a series of fusion proteins including GagBtk, CD16Btk and CD4Btk. Constitutive membrane association greatly enhanced the ability of Btk to transform Rat2 fibroblasts in the presence of high levels of Src activity. All membrane targeted forms of Btk were highly tyrosine phosphorylated. Transformation required membrane localization, Btk kinase activity, transphosphorylation by Src family kinases, and an intact SH2 domain but not the PH or SH3 domains. These data suggest that membrane localization is a critical early step in Btk activation.
引用
收藏
页码:1375 / 1383
页数:8
相关论文
共 50 条
  • [31] Bruton's tyrosine kinase: oncotarget in myeloma
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    ONCOTARGET, 2012, 3 (09) : 913 - 914
  • [32] Managing toxicities of Bruton tyrosine kinase inhibitors
    Lipsky, Andrew
    Lamanna, Nicole
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 336 - 345
  • [33] Bruton tyrosine kinase inhibitors for multiple sclerosis
    Kraemer, Julia
    Bar-Or, Amit
    Turner, Timothy J.
    Wiendl, Heinz
    NATURE REVIEWS NEUROLOGY, 2023, 19 (05) : 289 - 304
  • [34] Bruton Tyrosine Kinase Gene Mutations in Argentina
    Danielian, Silvia
    El-Hakeh, Jazmin
    Basilico, Guillermo
    Oleastro, Matias
    Rosenzweig, Sergio
    Feldman, Guillermina
    Berozdnik, Liliana
    Galicchio, Miguel
    Gallardo, Angela
    Giraudi, Vera
    Liberatore, Diana
    Maria Rivas, Eva
    Zelazko, Marta
    HUMAN MUTATION, 2003, 21 (04)
  • [35] Bruton Tyrosine Kinase Inhibitors Present and Future
    Burger, Jan A.
    CANCER JOURNAL, 2019, 25 (06): : 386 - 393
  • [36] Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes
    de Diego, Rebeca Perez
    Lopez-Granados, Eduardo
    Pozo, Maite
    Rodriguez, Cristina
    Sabina, Prado
    Ferreira, Antonio
    Fontan, Gurnersindo
    Garcia-Rodriguez, Maria Cruz
    Alemany, Susana
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (06) : 1462 - 1469
  • [37] Expression of Bruton's tyrosine kinase in osteoclasts
    Danks, L
    Horwood, NJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) : 1309 - 1309
  • [38] Signalling of Bruton's tyrosine kinase, Btk
    Mohamed, AJ
    Nore, BF
    Christensson, B
    Smith, CIE
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1999, 49 (02) : 113 - 118
  • [39] Nucleocytoplasmic shuttling of Bruton's tyrosine kinase
    Mohamed, AJ
    Vargas, L
    Nore, BF
    Bäckesjo, CM
    Christenssonn, B
    Smith, CIE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (51) : 40614 - 40619
  • [40] Bleeding Complications With Bruton Tyrosine Kinase Inhibitors
    Kessler, Craig M.
    DeLoughery, Thomas G.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 559 - 561